楚天科技(300358.SZ):全資子公司再次通過高新技術企業認定
格隆匯12月6日丨楚天科技(300358.SZ)公佈,公司全資子公司楚天華通於近日收到了由吉林省科學技術廳、吉林省財政廳、國家税務總局吉林省税務局聯合頒發的《高新技術企業證書》,楚天華通再次通過了高新技術企業的認定。
本次認定並取得證書系楚天華通原《高新技術企業證書》有效期滿後進行的重新認定。根據國家對高新技術企業的相關税收優惠政策,公司2021年、2022年、2023年可享受國家關於高新技術企業所得税優惠政策,按15%的税率繳納企業所得税。2021年度楚天華通已按15%的税率預繳企業所得税,本次通過高新技術企業複審所獲税收優惠政策不會對公司2021年度經營業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.